Membrane-type 1 matrix metalloproteinase is regulated by Sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells

Neoplasia

Volumn 9, Issue 5, 2007, Pages 406-417

  Sroka, Isis C ^a   Nagle, Raymond B ^a,b   Bowden, G Tim ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

AKT; MAP kinases; MT1 MMP; Prostate cancer; Sp1

Indexed keywords

INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR SP1;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 34249063875     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07193     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. Deryugina EI and Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25, 9-34.
3. Sounni NE and Noel A (2005). Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87, 329-342.
4. Overall CM and Lopez-Otin C (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2, 657-672.
5. Seiki M and Yana I (2003). Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 94, 569-574.
6. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, and Cher ML (1999). Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5, 4105-4110.
7. Cardillo MR, Di Silverio F, and Gentile V (2006). Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 26, 973-982.
8. 3 chain and induces cell migration. Cancer Res 63, 2292-2299.
9. Bair EL, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle RB, and Bowden GT (2005). Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia 7, 380-389.
10. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, and Seiki M (2005). Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem 280, 88-93.
11. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, and Saiki I (2000). Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 155, 173-179.
12. Jung M, Romer A, Keyszer G, Lein M, Kristiansen G, Schnorr D, Loening SA, and Jung K (2003). mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue. Prostate 55, 89-98.
13. Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, and Lichtinghagen R (2002). Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 50, 38-45.
14. Lohi J, Lehti K, Valtanen H, Parks WC, and Keski-Oja J (2000). Structural analysis and promoter characterization of the human membranetype matrix metalloproteinase-1 (MT1-MMP) gene. Gene 242, 75-86.
15. Haas TL, Stitelman D, Davis SJ, Apte SS, and Madri JA (1999). Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 274, 22679-22685.
16. Alfonso-Jaume MA, Mahimkar R, and Lovett DH (2004). Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochem J 380, 735-747.
17. Black AR, Black JD, and Azizkhan-Clifford J (2001). Sp1 and Kruppellike factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188, 143-160.
18. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, and Xie K (2003). Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9, 6371-6380.
19. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, and Xie K (2001). Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61, 4143-4154.
20. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, Pages G, O'Rourke DM, Bernhard E, et al. (2004). Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1 - independent mechanism. Mol Biol Cell 15, 4841-4853.
21. Reisinger K, Kaufmann R, and Gille J (2003). Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci 116, 225-238.
22. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, and Crippa MP (2004). MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104, 256-262.
23. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y, and Kawamura J (2003). Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 56, 319-325.
24. Onishi T, Yamakawa K, Franco OE, Kawamura J, Watanabe M, Shiraishi T, and Kitazawa S (2001). Mitogen-activated protein kinase pathway is involved in alpha6 integrin gene expression in androgen-independent prostate cancer cells: role of proximal Sp1 consensus sequence. Biochim Biophys Acta 1538, 218-227.
25. Chu S and Ferro TJ (2005). Sp1: regulation of gene expression by phosphorylation. Gene 348, 1-11.
26. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, and Esumi H (2004). ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24, 3526-3535.
27. Zhang D and Brodt P (2003). Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 22, 974-982.
28. Wang BW, Chang H, Lin S, Kuan P, and Shyu KG (2003). Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res 59, 460-469.
29. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, and Sato H (2004). Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 64, 1044-1049.
30. Mitra A, Chakrabarti J, Banerji A, Das S, and Chatterjee A (2006). Culture of human cervical cancer cells, SiHa, in the presence of fibronectin activates MMP-2. J Cancer Res Clin Oncol 25, 667-677.
31. Tanimura S, Asato K, Fujishiro SH, and Kohno M (2003). Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 304, 801-806.
32. Tran NL, Nagle RB, Cress AE, and Heimark RL (1999). N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 155, 787-798.
33. Merchant JL, Du M, and Todisco A (1999). Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 254, 454-461.
34. Milanini J, Vinals F, Pouyssegur J, and Pages G (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273, 18165-18172.
35. Milanini-Mongiat J, Pouyssegur J, and Pages G (2002). Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277, 20631-20639.
36. Kuo L, Chang HC, Leu TH, Maa MC, and Hung WC (2006). Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207, 729-734.
37. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, and Kreisberg JI (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8, 1168-1171.
38. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, and Liotta LA (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989.
39. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said WB, Isaacs WB, and Sawyers CL (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95, 5246-5250.
40. Uzgare AR, Kaplan PJ, and Greenberg NM (2003). Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55, 128-139.
41. Yang YM, Bos F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C, and Mercola D (2003). c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9, 391-401.
42. Grunwald V, DeGraffenried L, Russe D, Friedrichs WE, Ray RB, and Hidalgo M (2002). Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62, 6141-6145.
43. Udayakumar TS, Nagle RB, and Bowden GT (2004). Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 58, 66-75.
44. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, and Weber MJ (1999). Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59, 279-284.
45. Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A, and Tzivion G (2003). Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 278, 26715-26721.
46. Nicolas M, Noe V, and Ciudad CJ (2003). Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F. Biochem J 371, 265-275.
47. Abdelrahim M and Safe S (2005). Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68, 317-329.
48. Logan SK, Falasca M, Hu P, and Schlessinger J (1997). Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol Cell Biol 17, 5784-5790.